Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 44 |
| Active Pipeline (Recruiting Now) | 14 (10) |
| Completed vs Stopped Early | 7 / 2 (4.5%) |
| Median Closed Actual Enrollment | 43 participants |
| Physical Hospital Site Disclosure | 99.5% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Leiden University Medical Center | Leiden | 31 |
| Erasmus Medical Center | Rotterdam | 7 |
| University Medical Center Groningen | Groningen | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05393791 | Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC | Phase II | RECRUITING |
| NCT06275958 | DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer | Phase III | RECRUITING |
| NCT07018661 | [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer | Phase II/III | RECRUITING |
| NCT05255653 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Leiden University Medical Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.